Our findings are in agreement with previous studies that found metformin treatment suppresses the development of prostate and melanoma tumors by targeting STAT3 and NF-κB in cancer stem-like cells during the early inflammatory process (known to be associated with carcinogenesis) [42–44]. The gene discussed is NFKB1; the disease is cancer.